Sign Out
5 mg: Montelukast is indicated in the treatment of asthma as add-on therapy in those 6 to 14 years old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom "as-needed" short-acting β-agonists provide inadequate clinical control of asthma.
Montelukast may also be an alternative treatment option to low-dose inhaled corticosteroids for 6 to 14 years old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see Dosage & Administration).
Monlelukast is also indicated in the prophylaxis of asthma from 6 years of age and older in which the predominant component is exercise-induced bronchoconstriction.
Continue with Google